PDL/Roche Targeting Broad Zenapax Asthma Label Under Development Deal
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Roche/Protein Design Labs will pursue a broad moderate to severe asthma indication for Zenapax (daclizumab) in an attempt to gain an advantage over Xolair, under a co-development agreement announced Sept. 16.